Aurinia Pharmaceuticals Inc. (AUPH) Stock Price Down 3.2%
Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) fell 3.2% on Wednesday . The stock traded as low as $2.07 and last traded at $2.10, with a volume of 591,674 shares changing hands. The stock had previously closed at $2.17.
Several brokerages recently weighed in on AUPH. HC Wainwright increased their target price on Aurinia Pharmaceuticals from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, August 17th. Leerink Swann restated an “outperform” rating on shares of Aurinia Pharmaceuticals in a research note on Tuesday, August 16th. FBR & Co reaffirmed an “outperform” rating and issued a $9.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday, August 15th. Canaccord Genuity set a $10.00 price target on Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 5th. Finally, Zacks Investment Research raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $7.75.
The company’s 50-day moving average is $3.03 and its 200-day moving average is $2.78. The stock’s market capitalization is $70.58 million.
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.